Torcetrapib

• 产品号: PZ0170
• CAS号: 262352-17-0
• 分子式: C26H25F9N2O4
• 分子量: 600.4733288
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: Torcetrapib
• IUPAC标准名: ethyl (2R,4S)-4-({[3,5-bis(trifluoromethyl)phenyl]methyl}(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinoline-1-carboxylate
• IUPAC传统名: torcetrapib
• 别名: CP-529414; CP-529,414; (2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester

产品登记号

• CAS号: 262352-17-0
• MDL号: MFCD09260777

产品性质

• Empirical Formula (Hill Notation): C26H25F9N2O4
• 纯度: ≥98% (HPLC)
• 外观: white powder
• 比旋光度: [α]/D >-70°
• 溶解度: DMSO: >5 mg/mL
• GHS警示词: Warning
• GHS危险声明: H302
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 危险公开号: 22
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Torcetrapib is a Cholesteryl ester transfer protein (CETP) inhibitor. CETP normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL levels (the "good" cholesterol-containing particle) and reduces LDL levels (the "bad" cholesterol). Unfortunately clinical trials were stopped because of excessive all cause mortality. Reasons are still being investigated, but may be related to some off target effects such as an increase in aldosterone secretion not found in some other CETP inhibitors.

详细说明 (简体中文)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Torcetrapib is a Cholesteryl ester transfer protein (CETP) inhibitor. CETP normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL levels (the "good" cholesterol-containing particle) and reduces LDL levels (the "bad" cholesterol). Unfortunately clinical trials were stopped because of excessive all cause mortality. Reasons are still being investigated, but may be related to some off target effects such as an increase in aldosterone secretion not found in some other CETP inhibitors.